Health Care

4373 posts

Proteomics claims it can diagnose throat cancer with blood test

Proteomics International (ASX:PIQ) has popped +6% after reporting the "high accuracy" of its blood test for…
A man lies in a hospital bed receiving an IV drip.

‘Critical step’: Go for Recce’s Phase III trials after banking $15.8M in capital raise

Recce Pharmaceuticals (ASX:RCE) has successfully filled its coffers ahead of its Phase III clinical trials in Indonesia and Australia,
Model of a knee

Paradigm activates first Aus site for osteoarthritis drug trials

Paradigm Biopharmaceuticals Ltd has opened its first Australian site as part of a trial to assess…
Cardiovascular concept

Cardiex wins TGA greenlight; shares jump +11%

Cardiex Ltd (ASX:CDX) has popped +11% intraday to 4.7cps as the smallcap healthcare stock wins a…
Australia and Japanese flags

Dimerix launches key trial in Japan as recruitment kicks off

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking…
White pills pouring down a shoot at the AFT Pharmaceuticals company labratory.

Reshaped Combogesic deal sets ‘pleased’ AFT Pharma up to answer US demand

New Zealand drug maker AFT Pharmaceuticals (ASX:AFP) will continue working with United States distributor Hikma Pharmaceuticals to sell key
A Mayne Pharma worker in a lab surrounded by vials and bottles.

Mayne Pharma nosedive deepens as Cosette mulls scrapping $672M buy-up

Mayne Pharma Group (ASX:MYX) has been taking a beating in the markets this week, with company value as much
The Market Online Video

AFT Pharma sets new $300M target after reaching $200M revenue for FY25

AFT Pharmaceuticals Ltd has unveiled its financial results for FY2025, announcing that it has reached a…
The Market Online Video

This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for 
Medicaid concept

HeraMED slammed as US partner drops pregnancy tech; Medicaid changes bite

Nanocap health software company HeraMED (ASX:HMD) has been slammed on Monday as the company revealed its…